Restarting Mounjaro after 6 months: what your prescriber needs to know

Why six months changes the clinical picture

The tirzepatide in your system from your last pen is long gone. Mounjaro's half-life means it clears the body within a few weeks of the final dose, so six months represents a substantial washout. That is not a problem, it is simply a fact that shapes the restart decision.

What changes over six months of not being on treatment is appetite regulation, gastric emptying speed and, for most people, some degree of weight regain. Research into GLP-1 and dual-agonist medicines consistently shows that a significant proportion of the weight lost during treatment returns once it stops, particularly within the first year off treatment. If you stepped off at 15mg after a long titration and then stopped for six months, your current weight is almost certainly different from your end-of-treatment weight, and that difference is exactly the kind of clinical information a prescriber needs. The full tirzepatide overview covers how the medicine works at a mechanism level, which is useful context here.

There is also a tolerance point. The gradual titration schedule (starting at 2.5mg and stepping up in roughly four-week increments) exists partly because your digestive system needs time to adapt to slowed gastric emptying. After six months off, that adaptation has unwound. Starting again at, say, 10mg would very likely mean a sharp return of nausea, vomiting or other gastrointestinal symptoms. Your prescriber will weigh that up when deciding where to begin again.

The restarter's real decision: same dose, step back, or step further back?

This is the decision most people are actually wrestling with, and it sits firmly with your prescriber rather than with any guide or calculator. That said, UK clinical practice broadly supports restarting at a lower dose than the one you finished on, especially after a break of this length. A gap of three months might involve stepping back one or two levels; after six months the step-back is typically more conservative. If your break has been closer to four or five weeks, our guidance on restarting Mounjaro after a month covers what a shorter washout period usually means for your dose, and for those who have been off treatment for around eight weeks, the page on restarting Mounjaro after two months sets out how that mid-length gap is typically approached.

Factors your prescriber will consider include: how much weight has returned since stopping; any new health conditions or medications started in the interim; your previous tolerability profile (did you sail through titration, or did certain doses cause persistent nausea?); and whether you're restarting privately or have been referred through an NHS pathway. On the cost side, the treatment pricing page sets out what a private course includes, useful if you're planning the practicalities of restarting.

None of this is a reason to feel disheartened. The fact that you're considering restarting suggests Mounjaro worked for you. The gap doesn't erase that; it just means the restart needs a little more care. Think of it like starting a training programme again after an injury layoff, you don't go straight back to the same load on day one.

What to bring to the consultation

Coming prepared speeds things up considerably. The most useful things to have to hand: your previous dose (or the pen you last used, the dose is printed on the label, and if you kept one in the fridge door you may still have it); an honest record of any weight change since stopping; a list of any new medicines, supplements or conditions since your last clinical review; and any evidence of previous prescriptions if you're moving to a new provider.

If your previous treatment was through a different pharmacy or clinic, restarting with a regulated online pharmacy is entirely possible, you'll be asked to provide evidence of your treatment history as part of the clinical assessment. The prescriber reviewing your case will want to know the highest dose you reached and whether it was well tolerated, not just the dose you finished on. Our clinical team reviews every new and returning patient personally; no automated system makes the prescribing decision.

One practical note: if you have any unused pens still in the fridge from your previous course, check the expiry date before assuming they're usable. More importantly, do not restart at whatever dose those pens contain without a prescriber's say-so, the right dose for you now is not necessarily the one those pens are labelled at.

Safety considerations specific to a long restart

Restarting after a six-month gap isn't higher risk than a first-ever start, but there are a few things worth knowing before you go back in. The NHS patient guidance on tirzepatide (the NHS Medicines page for tirzepatide) covers the side-effect profile in plain language; the gastrointestinal effects that tend to be most prominent at the start of treatment or after a dose increase are the ones most likely to reappear if you restart at a dose your system isn't ready for.

Pancreatitis, though infrequent, is a recognised risk with GLP-1 class medicines. Severe stomach pain that spreads towards the back, with or without vomiting, warrants urgent medical attention. The MHRA flagged this specifically in a Drug Safety Update in January 2026 covering GLP-1 medicines. It's relevant background for anyone restarting. You can report any suspected side effects through the Yellow Card scheme, and doing so helps the MHRA build a clearer national picture of how these medicines perform in practice.

Contraception is worth revisiting too if you're a woman of reproductive age. For tirzepatide specifically, UK guidance recommends adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption can be affected. If this applies to you and you weren't aware of it during your previous course, raise it at the consultation. The broader Mounjaro information page covers this alongside other practical points for people on treatment.